|
PHILADELPHIA--Organized by Pharma IQ, a division of IQPC, the 4th Improving Solubility conference will be held March 29-31, 2010 at The Park Hyatt in Philadelphia, PA.
This forum brings together pharmaceutical researchers and scientists to uncover advances in enhancing solubility, amorphous forms, bioavailability & lipid-based formulation of drugs.
“[The conference provides a] great mix of technical details plus examples.”
Since the number of poorly soluble drugs coming to market have increased, many pharmaceutical companies are working on new techniques to measure, predict and improve the bioavailability of compounds. However, it remains unclear which method will be widely adopted to build successful drug compounds and maximize time-to-market.
Leading pharmaceutical and research organizations, including AstraZeneca, Merck, Novartis, Pfizer, Sanofi-Aventis, Bristol-Myers Squibb, H. Lundbeck, Hoffman La-Roche and GlaxoSmithKline. will present case studies and solutions on:
Nanocrystalline drug-polymer solid dispersions for poorly water-soluble drugs The role and function of solubility measurement from a central laboratory in drug discovery Implications of Biopharmaceutical Classification System (BCS): Solubility and permeability class on drug formulation Lipid-based drug delivery to effectively overcome physical and biological barriers Oral lipid-based formulations for the enhancement of poorly soluble compound delivery API crystal forms and their bioavailability Novel strategies for salt selection concerning solubility enhancement, salt stability and stabilization
Dr. Jeff Skell, Director of DMPK & Pharmaceutics, Drug & Biomaterial R&D at Genzyme and speaker at the 4th Improving Solubility commented on the conference series, stating: “Excellent networking and diverse sessions; good to have theoretical discourse.”
Past speaker, Dr. Debra Walker, Research Fellow at Merck & Co. adds, “[The conference provides a] great mix of technical details plus examples.”
Exhibitors at the 4th Improving Solubility conference include Eurand, CyDex Pharmaceuticals Inc, Catalent Pharma Solutions, Bend Research Inc, Aptuit, O’Brien Jones and others.
For more information about the 4th Improving Solubility conference, visit www.improvingsolubility.com. Follow Pharma IQ on Twitter at www.twitter.com/PharmaIQ or contact Simon Curtis, Pharma IQ Conference Director at
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
.
About IQPC
IQPC (www.iqpc.com) provides business executives with tailored practical conferences, large-scale events, topical seminars and in-house training programs. Producing over 1,500 events annually around the world, IQPC continues to grow and has offices in cities across six continents including: Berlin, Dubai, London, New York, Sao Paulo, Singapore, Stockholm, Sydney, and Toronto. BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read at the bottom of / About Us / Section
Add this page to your favorite Social Bookmarking websites
          
Trackback(0)
 |
TrackBack URI for this entry
Subscribe to this comment's feed
